Notice of AGM

RNS Number : 0205Q

Scancell Holdings Plc

08 October 2013

 



Scancell Holdings Plc

("Scancell" or the "Company")

Notice of Annual General Meeting

Scancell announces that the Annual General Meeting ("AGM") relating to the Company's financial year ended 30 April 2013, will be held at 11.00 a.m. on 1 November 2013 at the offices of FTI Consulting, Holborn Gate, 26 Southampton Buildings, London, WC2A 1PB

The Notice convening the AGM is being sent to shareholders today and will be available on the company's website www.scancell.co.uk

For Further Information:

Scancell Holdings Plc	+ 44 (0) 74 2323 0 497
Dr Richard Goodfellow, Joint CEO
Professor Lindy Durrant, Joint CEO
Cenkos Securities plc:	[phone]
Camilla Hume
Stephen Keys
FTI Consulting	[phone]
Simon Conway
Mo Noonan
Dr. Reuter Investor Relations	[phone]
Kim von Ahn

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope®  technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

 

END

 

 

NOABXBDGSSGBGXI